1. The A 2b adenosine receptor antagonist PSB-603 promotes oxidative phosphorylation and ROS production in colorectal cancer cells via adenosine receptor-independent mechanism
- Author
-
Christina Mølck, Frédéric Hollande, Laura M. Failla, Gregory D. Stewart, Joan K. Heath, Jean-Marc Pascussi, James G. Ryall, and Janine L Coates
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Chemistry ,Cancer ,Purinergic signalling ,Adenosine receptor antagonist ,medicine.disease ,Adenosine A3 receptor ,medicine.disease_cause ,Adenosine receptor ,Adenosine ,03 medical and health sciences ,030104 developmental biology ,Endocrinology ,Oncology ,Internal medicine ,medicine ,Cancer research ,Signal transduction ,Oxidative stress ,medicine.drug - Abstract
Purpose Adenosine is a multifaceted regulator of tumor progression. It modulates immune cell activity as well as acting directly on tumor cells. The A 2b adenosine receptor (A 2b -AR) is thought to be an important mediator of these effects. In this study we sought to analyze the contribution of the A 2b -AR to the behavior of colorectal cancer cells. Principal results The A 2b -AR antagonist PSB-603 changed cellular redox state without affecting cellular viability. Quantification of cellular bioenergetics demonstrated that PSB-603 increased basal oxygen consumption rates, indicative of enhanced mitochondrial oxidative phosphorylation. Unexpectedly, pharmacological and genetic approaches to antagonize AR-related signalling of PSB-603 did not abolish the response, suggesting that it was AR-independent. PSB-603 also induced acute increases in reactive oxygen species, and PSB-603 synergized with chemotherapy treatment to increase colorectal cancer cell death, consistent with the known link between cellular metabolism and chemotherapy response. Major conclusions PSB-603 alters cellular metabolism in colorectal cancer cells and increases their sensitivity to chemotherapy. Although requiring more mechanistic insight into its A 2b -AR-independent activity, our results show that PSB-603 may have clinical value as an anti-colorectal cancer therapeutic.
- Published
- 2016
- Full Text
- View/download PDF